News | January 12, 2023
Merck completes tender offer to acquire Imago BioSciences
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
As a result, Imago will become a subsidiary of Merck.
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Acquisition expands Merck’s growing hematology portfolio
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
One in two women with advanced ovarian cancer has an HRD-positive tumor
Subscribe To Our Newsletter & Stay Updated
